MX2021012197A - Polipeptidos de ectonucleotido pirofosfatasa (enpp1) y metodos de uso de los mismos. - Google Patents

Polipeptidos de ectonucleotido pirofosfatasa (enpp1) y metodos de uso de los mismos.

Info

Publication number
MX2021012197A
MX2021012197A MX2021012197A MX2021012197A MX2021012197A MX 2021012197 A MX2021012197 A MX 2021012197A MX 2021012197 A MX2021012197 A MX 2021012197A MX 2021012197 A MX2021012197 A MX 2021012197A MX 2021012197 A MX2021012197 A MX 2021012197A
Authority
MX
Mexico
Prior art keywords
methods
same
enpp1
polypeptides
enpp1 polypeptides
Prior art date
Application number
MX2021012197A
Other languages
English (en)
Inventor
Demetrios Braddock
Paul Stabach
Original Assignee
Univ Yale
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Yale filed Critical Univ Yale
Publication of MX2021012197A publication Critical patent/MX2021012197A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/04—Phosphoric diester hydrolases (3.1.4)
    • C12Y301/04001—Phosphodiesterase I (3.1.4.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y306/00—Hydrolases acting on acid anhydrides (3.6)
    • C12Y306/01—Hydrolases acting on acid anhydrides (3.6) in phosphorus-containing anhydrides (3.6.1)
    • C12Y306/01009—Nucleotide diphosphatase (3.6.1.9), i.e. nucleotide-pyrophosphatase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

LA PRESENTE DESCRIPCIÓN INCLUYE POLIPÉPTIDOS MUTANTES ENPP1 CON VIDA MEDIAS MEJORADAS IN VIVO.
MX2021012197A 2019-04-05 2020-04-03 Polipeptidos de ectonucleotido pirofosfatasa (enpp1) y metodos de uso de los mismos. MX2021012197A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201962830230P 2019-04-05 2019-04-05
US202062983142P 2020-02-28 2020-02-28
US202062984650P 2020-03-03 2020-03-03
PCT/US2020/026643 WO2020206302A1 (en) 2019-04-05 2020-04-03 Enpp1 polypeptides and methods of using same

Publications (1)

Publication Number Publication Date
MX2021012197A true MX2021012197A (es) 2022-01-06

Family

ID=72667412

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021012197A MX2021012197A (es) 2019-04-05 2020-04-03 Polipeptidos de ectonucleotido pirofosfatasa (enpp1) y metodos de uso de los mismos.

Country Status (12)

Country Link
US (1) US20220195402A1 (es)
EP (1) EP3947660A4 (es)
JP (1) JP2022527557A (es)
KR (1) KR20210149146A (es)
CN (1) CN113993993A (es)
AU (1) AU2020256253A1 (es)
BR (1) BR112021020037A2 (es)
CA (1) CA3136118A1 (es)
IL (1) IL286946A (es)
MX (1) MX2021012197A (es)
TW (1) TW202043292A (es)
WO (1) WO2020206302A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4162036A1 (en) 2020-06-09 2023-04-12 Inozyme Pharma, Inc. Soluble enpp1 or enpp3 proteins and uses thereof
WO2023191898A1 (en) * 2022-03-30 2023-10-05 Yale University Method and compositions for treatment, amelioration, and/or prevention of diffuse idiopathic skeletal hyperostosis (dish)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2179383A1 (en) * 1994-01-14 1995-07-20 Ira D. Goldfine Antagonists to insulin receptor tyrosine kinase inhibitor
DK3460054T3 (da) * 2013-03-15 2021-01-18 Atyr Pharma Inc Histidyl-tRNA-syntetase-Fc-konjugater
JP6995627B2 (ja) * 2015-05-19 2022-02-04 イエール ユニバーシティ 病的石灰化状態を治療するための組成物およびそれを使用する方法

Also Published As

Publication number Publication date
US20220195402A1 (en) 2022-06-23
WO2020206302A1 (en) 2020-10-08
TW202043292A (zh) 2020-12-01
AU2020256253A1 (en) 2021-10-28
EP3947660A4 (en) 2023-01-25
CA3136118A1 (en) 2020-10-08
BR112021020037A2 (pt) 2021-12-07
CN113993993A (zh) 2022-01-28
IL286946A (en) 2021-12-01
KR20210149146A (ko) 2021-12-08
JP2022527557A (ja) 2022-06-02
EP3947660A1 (en) 2022-02-09

Similar Documents

Publication Publication Date Title
AU201813151S (en) An oral appliance
MX2022007754A (es) Nuevos agonistas de il2 y metodos de uso de estos.
MX2017009937A (es) Cepas fungicas y metodos de uso.
MX2021002367A (es) Productos de papel aislado y repulpable, metodos para fabricarlos y usarlos.
MX2021004906A (es) Conjugados de anticuerpo modificado con cisteína-fármaco con enlazadores que contienen péptidos.
MX2020005170A (es) Formulaciones de proteinas de fusion vegfr-fc.
MX2019004487A (es) Metodos y composiciones para el tratamiento de la enfermedad de fabry.
MX2020006901A (es) Composiciones de pares de bases no naturales y procedimientos de uso.
AU201813153S (en) An oral appliance
MX2020013421A (es) Composiciones de dióxido de silicio de carbono poroso biogénico, métodos de elaboracion y uso de estas.
PH12020551336A1 (en) Anti-klk5 antibodies and methods of use
MX2021012197A (es) Polipeptidos de ectonucleotido pirofosfatasa (enpp1) y metodos de uso de los mismos.
AU201816899S (en) Grater
MX2021013416A (es) Polipeptidos de union al antigeno cd33 y sus usos.
MX2021016050A (es) Formulaciones transdermicas.
MX2022012832A (es) Formas cristalinas y metodos de produccion de las mismas.
AU201813963S (en) Oral appliance
AU201813962S (en) Oral appliance
AU201813965S (en) Oral appliance
MX2021012813A (es) Conjugados de citocina de liberacion lenta.
AU201816903S (en) Desktop video processor
AU201813964S (en) Oral appliance
AU201814961S (en) Measuring scoop
AR118586A1 (es) Polipéptidos enpp1 y sus métodos de uso
MX2021007200A (es) Complejo de zinc-arginina-cloruro.